Predicting disease outcome after the diagnosis of breast cancer, which is important for the choice of treatment of women diagnosed with this malignancy, remains a major challenge. Over the past decade there has been an increas ing awareness of the power of genetic prediction, which is now beginning to provide some information that may be useful in the assessment of disease outcome. As an example, several reports in the literature indicate that genetic signatures are potentially useful approaches for prognostication. A major impediment to rapid progress in the identifi cation of genetic determinants of outcome has been, and continues to be, our limited ability to assess gene-gene and gene-environment interactions. Never theless, inroads into understanding gene-gene interactions are being made due, in part, to a better appreciation of molecular pathway analysis. Particularly attractive targets of study have been genetic polymorphisms in genes associated with the repair of DNA damage and those involved in cell cycle control since an inability to tightly regulate either of these two processes is likely to result in a less than optimal outcome.
In the report by Schimdt and colleagues [1] the genegene interaction between the cell cycle checkpoint control gene P53 and its negative regulator MDM2 has been examined in a large group of women diagnosed with breast cancer to determine whether two single nucleo tide polymorphisms (SNPs), R72P in P53 (rs1042522) and MDM2-309 (rs2279744), could be asso ciated with disease outcome. Th is is not the fi rst study to examine the relationship between the tumour suppressor gene P53 and MDM2, but it is one of the fi rst to investigate the relationship between polymorphisms in these genes and disease outcome as opposed to breast cancer risk. Th e importance of the two SNPs lies in their functional consequence. R72 is reported to have a 15-fold greater capacity to induce apoptosis than P72 [2] and the MDM2 polymorphism has been shown to be associated with defi ciencies in the P53 response pathway [3] .
Studies examining the relationship between R72P and MDM2-309 and cancer risk have been somewhat inconsistent, but many larger studies examining common malignancies (including breast cancer) are converging towards the notion that neither SNP appears to be associated with the risk of developing disease [4] [5] [6] [7] [8] . Th ese results are in contrast, however, to investigations into cancers developing in patients diagnosed with germline P53 mutations, where both R72P and MDM2-309 SNPs do appear to be associated with diff erences in the age at which disease is diagnosed [3,9,10]. Th is is perhaps not surprising as loss of P53 will underlie subsequent events associated with tumour development in this setting.
Th e pooled analysis presented by Schmidt and colleagues [1] of four studies, three hospital-and one
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population-based, including 3,749 breast cancer patients, provided suffi cient power to detect whether or not there were any associations between the combined polymorphisms and disease outcome. Th e results revealed that there is an association between the two SNPs and breast cancer outcome, suggesting that they could be used as potential markers to stratify patients into diff erent risk groups. Nevertheless, even with this large number of patients only 26 were homozygous for both variants, thereby making it impossible to quantify statistically the stron gest eff ect. Th is emphasizes the necessity of acquiring large numbers of patients for genetic studies since smaller ones run the risk of having insuffi cient power to detect these types of eff ect. Th e magnitude of the eff ect, however, remains relatively small (with an 11% diff erence) and emphasises the point that these two markers account for only some of the diff erences between patients with good or poor survival.
Previously, Schmidt and colleagues [8] had demon strated for breast cancer that neither R72P nor MDM2-309 was associated with the risk of developing disease, which was supported by several other larger studies [4] [5] [6] [7] . Placing this in context, the results of Schmidt and colleagues [1] are signifi cant as they indicate that R72P and MDM2-309 act as aff ect modifi ers as opposed to being causal. If R72P and MDM2-309 are indeed aff ect modifi ers, then further studies in diff erent populations should yield similar results as the eff ects of the two SNPs would be predicted to be similar in diverse groups of patients. In support of this, the results are consistent with a report by Do and colleagues [11] , who identifi ed that both polymorphisms also act as disease modifi ers in lymphoblastic leukaemia.
Since the advent of gene expression array technology, it is now well recognised that there are multiple subgroups of breast cancer that can be characterised not only by their histopathology but also by gene expression profi ling and that these diff erences are correlated with disease survival [12] [13] [14] . In relation to R72P and MDM2-309, it would be predicted that these two SNPs, acting as disease modifi ers, are likely to remain associated with survival even in diff erent subgroups of patients as they would still remain aff ect-modifi ers and continue to contribute to disease progression irrespective of the molecular profi le of the tumour.
Finally, this study and those that have preceded it raise important points in relation to the choice of disease in which to examine polymorphisms in two key regulators of cell cycle checkpoint control. If one of the primary molecular alterations involves P53, then it is to be expected that diff erences in the remaining wild-type P53 allele (or its downstream partners) will be infl uenced by intrinsic functional polymorphisms, which are likely to correlate with the age at disease diagnosis. If P53 is not involved in a disease's initiation but in its progression, then it is more prone to be associated with diff erences in prognosis. Th e report by Schmidt and colleagues [1] has signifi cantly contributed to our understanding of risk recurrence in patients diagnosed with breast cancer. It is to be expected that with larger, more defi nitive studies, more precise information about the role of R72P and MDM2-309 in disease outcome will be forthcoming.
Abbreviations SNP = single nucleotide polymorphisms.
